Drug Trial Radar · NCT07933055
Phase 1b/2 to Evaluate the Safety, Tolerability, and Efficacy of TXN10128 in Combination With TOPO-I Inhibitor-based Therapies (Irinotecan or TROP2 ADC) in Advanced or Metastatic EGFR Mutated NSCLC
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
104
Planned (sponsor's estimate)
Start
Oct 8, 2026
Primary completion
Sep 30, 2028
Study completion Mar 31, 2029
Sponsor
- Lead sponsor
- Txinno Bioscience Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, multi-cohort, Phase 1b/2 clinical study. This study evaluates TXN10128 in combination with either irinotecan (a topoisomerase I inhibitor) or a TROP2-directed antibody-drug conjugate (TROP2 ADC) in participants with advanced or metastatic NSCLC with confirmed EGFR mutations. The study consists of three cohorts. It enrolls participants who have progressed after prior treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI) and platinum-based doublet chemotherapy. Part B enrolls participants who are currently receiving TROP2 ADC therapy or whose disease has progressed following such therapy (with no restriction on the number of prior lines). In Part C, participants who are naïve to TROP2 ADC therapy and have received no more than three prior lines of systemic anticancer therapy will be enrolled. A safety run-in will first be conducted to confirm the safety of the combination with a TROP2 ADC. Based on the results, the Safety Review Committee (SRC) will select the recommended dose for expansion phase, which will follow Simon's two-stage design.
Conditions
- NSCLC (Non-small Cell Lung Cancer)
Interventions
TXN10128Drug
oral ENPP1 inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free SurvivalTime frame: From enrollment until disease progression or the end of the study; tumor assessments every 8 weeks through Week 24 and every 12 weeks thereafter.
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Ajou University Hospital
Gyeonggi-do, South Korea · Recruiting
Seoul University Bundang Hospital
Gyeonggi-do, South Korea · Recruiting
The Catholic University of Korea, ST. Vincent's Hospital
Gyeonggi-do, South Korea · Not yet recruiting
Gachon University Gil Medical Center
Incheon, South Korea · Recruiting
HanYang Univ. Hospital
Seoul, South Korea · Recruiting
Korea University Guro Hospital
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Not yet recruiting
Severance Hospital
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.